Nonprescription Nexium heartburn medicine launches (Update)

by Linda A. Johnson

A nonprescription version of Nexium, the most popular medicine for frequent, severe heartburn, has just gone on sale.

Drugmaker Pfizer Inc. said Tuesday that over-the-counter Nexium 24HR is available for online orders at www.Nexium24HR.com and will be in most retailers nationwide within three days.

The nonprescription version is a 20-milligram dose of "the purple pill," known chemically as esomeprazole.

Patients are to take one pill daily for up to 14 days, so it's sold in packages of 14, 28 or 42 pills, priced at about $15 to $30. Prescription Nexium, which will still be available in 20- and 40-milligram strengths, costs $260 a month or more, without insurance coverage.

New York-based Pfizer said it's planning consumer ads about the launch, which it's begun promoting at www.facebook.com/Nexium24HR . Pfizer also is offering $1-off coupons for it on the website and www.coupons.com .

In 2012, Pfizer acquired exclusive worldwide rights to nonprescription Nexium from maker AstraZeneca PLC. The British drugmaker got a payment of $250 million and will receive royalties and other payments based on the level of sales.

AstraZeneca will manufacture the nonprescription version for Pfizer and continue selling prescription Nexium, which can take one to four days for full effect. It's heavily advertised as "the purple pill that can provide 24-hour relief from persistent heartburn" caused by acid reflux disease. Unlike antacids, Nexium blocks the "pumps" that release acid into the stomach.

The Food and Drug Administration approved over-the-counter Nexium 24HR two months ago.

Last year, Nexium was the sixth-best-selling prescription drug in the world, generating revenue of $7.86 billion, up 7 percent from 2012 sales, according to health data firm IMS Health. Competition from the nonprescription version likely will reduce sales in the future.

Over the past month, Pfizer repeatedly courted AstraZeneca, offering as much as $119 billion to buy the company in what would have been the biggest pharmaceutical acquisition ever. After repeated rebuffs, Pfizer ended its pursuit Monday.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Canadian study OKs Losec and Nexium

Feb 27, 2008

Health Canada has completed a review of safety information for Losec (omeprazole) and Nexium (esomeprazole) and found no increased cardiovascular risks.

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack ...

AstraZeneca fends off Pfizer with new growth plan

May 06, 2014

AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

12 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments